ClinicalTrials.gg
CompletedNCT05788705Updated Oct 26, 2026

Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis

An interventional study of Green Tea Polyphenolics (EGCG) and Chamomile (Matricaria recutita) in Rheumatoid Arthritis, sponsored by Adel A.Gomaa. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Adel A.Gomaa · Not applicable, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now CompletedFirst site in Egypt+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Arthritis, Rheumatoid with a site in Egypt — 35 open to participants now, 36 under way, 9 of them phase 3. Arthritis, Rheumatoid · Egypt.

Enrollment
30th of 56
60 · median 68
Started
2025
with 8 others
No phase
18 of 88
4 open now
Registered
48th of 88
by date

Among the 88 studies in Arthritis, Rheumatoid with a site in Egypt, this one is the 30th largest by enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2025, is one of 18 with no phase, and was the 48th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

35 of the 88 studies in Arthritis, Rheumatoid with a site in Egypt are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Arthritis, Rheumatoid with a site in Egypt, or all of them as a file.
02

Study summary

There is no treatment that could utterly cure Rheumatoid arthritis (RA), but the disease is mainly improved by conventional disease-modifying anti rheumatic drugs. Methotrexate and biological DMARDs as JAK-STAT inhibitors may be used to control and delay the progression of the disease and improve the quality of lives of patients. However, DMARDs have deleterious effects on human health. Several natural products have been reported to exert inhibitory effects on the JAK-STAT signaling pathway, including green tea extract, chamomile extract, and licorice extract.

Read the detailed description

Rheumatoid arthritis (RA) is a chronic, progressive, systemic autoimmune disease characterized by inflammatory cell infiltration and synovial proliferation, accompanied by progressive damage to articular cartilage and subchondral bone. The prevalence of RA is approximately 3.6% in women and 1.7% in men. Although there is currently no definitive cure for RA, disease activity and progression can be effectively controlled with conventional disease-modifying antirheumatic drugs (DMARDs), including methotrexate, as well as biological and targeted synthetic DMARDs. However, the long-term use of these agents may be associated with various adverse effects, highlighting the need for safe and effective complementary therapeutic approaches.

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway plays an important role in the regulation of inflammatory and immune responses in RA. Activation of this pathway by cytokines, particularly interleukin-6 (IL-6), contributes to the persistence of synovial inflammation and disease activity. Therefore, modulation of the JAK-STAT signaling pathway represents a potential therapeutic approach in RA. Several studies have demonstrated that natural plant-derived compounds and extracts possess immunomodulatory and anti-inflammatory properties and may interfere with the JAK-STAT pathway, thereby reducing the production or signaling of pro-inflammatory cytokines.

Among these natural products, licorice (Glycyrrhiza glabra) contains several bioactive constituents, particularly glycyrrhizin, which has been reported to attenuate inflammatory signaling and inhibit components of the JAK-STAT pathway. Glycyrrhizin has been shown to reduce JAK/STAT signaling and may exert anti-inflammatory effects through modulation of IL-6-related signaling. Similarly, chamomile (Matricaria chamomilla) is rich in flavonoids, including apigenin, which has demonstrated anti-inflammatory and immunomodulatory activities. Apigenin has been reported to inhibit JAK1/2 and STAT3 phosphorylation and to reduce inflammatory cytokine production, supporting its potential role in the modulation of JAK-STAT-mediated inflammatory responses.

Green tea (Camellia sinensis) is another natural product rich in polyphenolic compounds, particularly catechins, with epigallocatechin-3-gallate (EGCG) being one of its major bioactive constituents. Green tea polyphenols have demonstrated anti-inflammatory and immunomodulatory effects and have been reported to interfere with JAK-STAT signaling. EGCG has been shown to suppress JAK1/JAK2 and STAT3 activation and to reduce the production of pro-inflammatory cytokines, including IL-6. These effects suggest that green tea extract may contribute to attenuation of inflammatory responses involved in RA and may have potential as a complementary therapeutic intervention.

Collectively, the reported anti-inflammatory and immunomodulatory properties of green tea, chamomile, and licorice, together with their potential effects on JAK-STAT signaling, provide a rationale for investigating these natural products as complementary therapies in RA. Therefore, the present study aimed to assess the efficacy of selected natural JAK-STAT pathway inhibitors, namely green tea, chamomile, and licorice, as complementary medicine in the treatment of patients with rheumatoid arthritis and to evaluate their potential role in attenuating treatment-related adverse effects.

our Research outcome measures:

  1. Primary (main):

    1. The change in DAS28 based on Erythrocyte Sedimentation Rate (DAS28-ESR) and the Clinical Disease Activity Index (CDAI)
    2. Rate of achieving 20% improvement in the American College Rheumatology criteria (ACR20).
    3. Change in visual analogue scale (VAS).
    4. Determination of Inflammatory cytokines levels: (Tumor necrosis factor α or Interleukin 6).
  2. Secondary (subsidiary):

    1. physician's global assessment
    2. Determination of synovitis musculoskeletal ultrasound (MSUS) 3.Safety and Tolerability Measures: adverse events including nausea, vomiting, dizziness and abdominal pain, CBC as well as kidney and liver function tests will be performed before enrolment and after treatment.
03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female,ages18-60.
  • Patients who met criteria for the diagnosis of RA
  • Patients who were signed the form.

Exclusion criteria

Exclusion Criteria:

  • Patients with Malignant tumours,
  • Patients with Infectious diseases,
  • Patients with Hematologic diseases.
  • Patients with other rheumatic diseases.
  • Women who are pregnant or breastfeeding.

    • to dietary supplement used in this study.
    • Hypertensive patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    "Green tea"

    Patients will receive two tablet green tea extract each tablet containing 300 mg of extract, equivalent to 90 mg of polyphenols twice daily (resulting in a total daily dose equivalent to 180 mg of green tea polyphenols) for 4 months

    Dietary Supplement: Green Tea Polyphenolics (EGCG)

  • Active comparator
    "chamomile"

    received ChE by steeping two chamomile flower tea bags (2 g per bag) in half a cup of hot water once daily in the evening for 4 months, providing a total daily dose of 40 mg of total flavonoids per 4 g of chamomile flowers for 4 months

    Dietary Supplement: Chamomile (Matricaria recutita)

  • Active comparator
    licorice

    Patients in third group received LE syrup, at a dose of 15 mL three times daily (200 mg licorice extract /day) for 4 months.

    Dietary Supplement: Licorice

  • Placebo comparator
    placebo

    tablets contained 100 mg of hydroxypropyl methylcellulose (HPMC) for 4 months

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementEpigallocatechin gallateStudies of Epigallocatechin gallateEpigallocatechin gallate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    this group took two GTE tablets with each tablet containing 300 mg of extract, equivalent to 90 mg of polyphenols twice daily (resulting in a total daily dose equivalent to 180 mg of green tea polyphenols) for 4 months

  • Dietary supplementMatricaria recutitaStudies of Matricaria recutitaMatricaria recutita pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients in the second group received ChE by steeping two chamomile flower tea bags (2 g per bag) in half a cup of hot water once daily in the evening for 4 months, providing a total daily dose of 40 mg of total flavonoids per 4 g of chamomile flowers for four months

  • Dietary supplementGlycyrrhiza glabra extractStudies of Glycyrrhiza glabra extractGlycyrrhiza glabra extract pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients in third group received LE syrup, at a dose of 15 mL three times daily (200 mg licorice extract /day) for four months.

  • Dietary supplementPlacebo

    The placebo tablets contained 100 mg of hydroxypropyl methylcellulose (HPMC) for four months

06

What researchers measure

Primary outcomes

  1. The change in DAS28 based on Erythrocyte sedimentation rate (DAS28-ESR)

    DAS-28 score: a DAS-28 score \> 5.1 indicating high disease activity; 3.2\< DAS-28 score≤5.1 indicates moderate disease activity; 2.6\< DAS-28 score≤3.2 indicates low disease activity; DAS-28 score≤2.6 indicates basic disease remission

    Time frame: Before the intervention, 4months after the intervention.

Secondary outcomes

  1. Change in visual analogue scale (VAS

    each patient will be asked to indicate his or her current level of pain on 100mm scale.0scale indicate no pain and 100mm indicate worst pain imaginable

    Time frame: Before the intervention, and 4 months after the intervention

  2. Determination of synovitis on musculoskeletal ultrasound(MSUS)

    Determination of synovitis on musculoskeletal ultrasound

    Time frame: Before the intervention, and 4months after the intervention

  3. Determination of Inflammatory cytokines levels: (Tumour necrosis factor α OR Interleukin 6).

    laboratory test

    Time frame: Before the intervention, and 4months after the intervention

07

Study locations

1 site
  • Assiut university
    Asyut, Egypt
08

References and documents

Publications

  • Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Epub 2016 May 3. PubMed 27156434 ↗
  • Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018 Apr 27;6:15. doi: 10.1038/s41413-018-0016-9. eCollection 2018. PubMed 29736302 ↗
  • Oton T, Carmona L. The epidemiology of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2019 Oct;33(5):101477. doi: 10.1016/j.berh.2019.101477. Epub 2020 Jan 25. PubMed 31987685 ↗
  • Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. PubMed 35081280 ↗
  • Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2023 Feb;82(2):182-188. doi: 10.1136/ard-2022-222824. Epub 2022 Oct 5. PubMed 36198438 ↗
  • Yang J, Wang L, Guan X, Qin JJ. Inhibiting STAT3 signaling pathway by natural products for cancer prevention and therapy: In vitro and in vivo activity and mechanisms of action. Pharmacol Res. 2022 Aug;182:106357. doi: 10.1016/j.phrs.2022.106357. Epub 2022 Jul 19. PubMed 35868477 ↗
  • Dudics S, Langan D, Meka RR, Venkatesha SH, Berman BM, Che CT, Moudgil KD. Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome. Int J Mol Sci. 2018 Aug 24;19(9):2508. doi: 10.3390/ijms19092508. PubMed 30149545 ↗
  • Kumar R, Singh S, Saksena AK, Pal R, Jaiswal R, Kumar R. Effect of Boswellia Serrata Extract on Acute Inflammatory Parameters and Tumor Necrosis Factor-alpha in Complete Freund's Adjuvant-Induced Animal Model of Rheumatoid Arthritis. Int J Appl Basic Med Res. 2019 Apr-Jun;9(2):100-106. doi: 10.4103/ijabmr.IJABMR_248_18. PubMed 31041173 ↗
  • Wu X, Wang W, Chen Y, Liu X, Wang J, Qin X, Yuan D, Yu T, Chen G, Mi Y, Mou J, Cui J, Hu A, E Y, Pei D. Glycyrrhizin Suppresses the Growth of Human NSCLC Cell Line HCC827 by Downregulating HMGB1 Level. Biomed Res Int. 2018 Jan 15;2018:6916797. doi: 10.1155/2018/6916797. eCollection 2018. PubMed 29568761 ↗
  • Wu Y, Wang Z, Du Q, Zhu Z, Chen T, Xue Y, Wang Y, Zeng Q, Shen C, Jiang C, Liu L, Zhu H, Liu Q. Pharmacological Effects and Underlying Mechanisms of Licorice-Derived Flavonoids. Evid Based Complement Alternat Med. 2022 Jan 17;2022:9523071. doi: 10.1155/2022/9523071. eCollection 2022. PubMed 35082907 ↗
  • Abid R, Ghazanfar S, Farid A, Sulaman SM, Idrees M, Amen RA, Muzammal M, Shahzad MK, Mohamed MO, Khaled AA, Safir W, Ghori I, Elasbali AM, Alharbi B. Pharmacological Properties of 4', 5, 7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways. Molecules. 2022 Jul 4;27(13):4304. doi: 10.3390/molecules27134304. PubMed 35807549 ↗

Individual participant data

Plan to share: Yes — Data will become available to interested investigators upon submitting a reasonable research request by email to A. Gomaa (a.gomma@aun.edu.eg).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: July, 2025

Access criteria: Data will become available to interested investigators upon submitting a reasonable research request by email to A. Gomaa (a.gomma@aun.edu.eg).

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jun 2026, 13 months.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 13 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Jul 2023 → Apr 2025, primary completion Jul 2025 → Jun 2026 and completion Dec 2025 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 29, 2023
StartActual
Apr 5, 2025was Jul 2023
Primary completionActual
Jun 1, 2026was Jul 2025
CompletionActual
Oct 1, 2026was Dec 2025
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 26, 2026
Sites
1 site added — first site in Egypt
Show site
  • Assiut university · Asyut, Egypt
Oct 26, 2026
Start date
Jul 2023→Apr 5, 2025 (actual)
Oct 26, 2026
Primary completion
Jul 2025→Jun 1, 2026 (actual)
Oct 26, 2026
Study completion
Dec 2025→Oct 1, 2026 (actual)
Oct 26, 2026
Enrollment
75 (estimated)→60 (actual)
Oct 26, 2026
Interventions
Changed "placebo"→Placebo. Added Dietary supplement: Green Tea Polyphenolics (EGCG)·Dietary supplement: Chamomile (Matricaria recutita)·Dietary supplement: Licorice; removed Dietary supplement: "apigenin" and "glycyrrhizin"·Dietary supplement: "glycyrrhizin" and "boswellic acid". Arm changed "placebo"→"chamomile". Arms added: "Green tea"·licorice·placebo; arms removed: "apigenin" and "glycyrrhizin"·"boswellic acid" and "glycyrrhizin"
Oct 26, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe change in DAS28 based on C-reactive proteinErythrocyte sedimentation rate (DAS28-CRPESR)Time frame: Before the intervention, 3 months after the intervention, and 6 months after the intervention → Before the intervention, 4months after the intervention.
Oct 26, 2026
Secondary outcomes
2 edited, 1 time frame changed
What changed in the outcomes
  • EditedDetermination of effusion synovitis volume on musculoskeletal ultrasound(MSUS)Time frame: Before the intervention, 3 months after the intervention, and 6 months after the intervention → Before the intervention, and 4months after the intervention
  • EditedDetermination of Inflammatory cytokines levels: (Tumour necrosis factor α andOR Interleukin 6).Time frame: Before the intervention, 3 months after the intervention, and 6 months after the intervention → Before the intervention, and 4months after the intervention
  • Time frameChange in visual analogue scale (VASBefore the intervention, 3 months after the intervention, and 6 months after the intervention → Before the intervention, and 4 months after the intervention
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Completed
    1 site added — first site in Egypt
    Show site
    • Assiut university · Asyut, Egypt
    Start date Jul 2023→Apr 5, 2025 (now actual)
    Primary completion Jul 2025→Jun 1, 2026 (now actual)
    Study completion Dec 2025→Oct 1, 2026 (now actual)
    Enrollment 75 (estimated)→60 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe change in DAS28 based on C-reactive proteinErythrocyte sedimentation rate (DAS28-CRPESR)Time frame: Before the intervention, 3 months after the intervention, and 6 months after the intervention → Before the intervention, 4months after the intervention.
    Secondary outcomes 2 edited, 1 time frame changed
    What changed in the outcomes
    • EditedDetermination of effusion synovitis volume on musculoskeletal ultrasound(MSUS)Time frame: Before the intervention, 3 months after the intervention, and 6 months after the intervention → Before the intervention, and 4months after the intervention
    • EditedDetermination of Inflammatory cytokines levels: (Tumour necrosis factor α andOR Interleukin 6).Time frame: Before the intervention, 3 months after the intervention, and 6 months after the intervention → Before the intervention, and 4months after the intervention
    • Time frameChange in visual analogue scale (VASBefore the intervention, 3 months after the intervention, and 6 months after the intervention → Before the intervention, and 4 months after the intervention
    Interventions Changed "placebo"→Placebo. Added Dietary supplement: Green Tea Polyphenolics (EGCG)·Dietary supplement: Chamomile (Matricaria recutita)·Dietary supplement: Licorice; removed Dietary supplement: "apigenin" and "glycyrrhizin"·Dietary supplement: "glycyrrhizin" and "boswellic acid". Arm changed "placebo"→"chamomile". Arms added: "Green tea"·licorice·placebo; arms removed: "apigenin" and "glycyrrhizin"·"boswellic acid" and "glycyrrhizin"
    + 5 other changes: index terms, verification date, description, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05788705
Lead sponsor
Adel A.Gomaa
Responsible party
Adel A.Gomaa (PROF OF CLINICAL PHARMACOLOGY, Assiut University) — Sponsor-investigator
First posted
Mar 29, 2023
Start date
Apr 5, 2025
Primary completion
Jun 1, 2026
Completion
Oct 1, 2026
Last update
Oct 26, 2026

Study contacts

Adel A Gomaa, Ph.D.
study chair · Faculty of Medicine, Assiut University, Egypt
Safaa A Mahran, MD
study director · Assiut University Hospital, Egypt

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Epigallocatechin gallate · Matricaria recutita · Glycyrrhiza glabra extract

Start the discussion